TO DOOR YEATY

PCT/PTO 08 OCT 200

PCT

(PCT Article 36 and Rule 70)

1 6 JAN 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPORT WIPO

/IPO	PCT

Applicant's or agent's file reference PCT 21080	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No.	International filing date (day/mo	onth/year) Priority date (day/month/year)
PCT/US03/12509 International Patent Classification (IPC)	11 April 2003 (11.04.2003)	16 April 2002 (16.04.2002)
1		
IPC(7): C12Q1/70; G01N 33/53; C12N Applicant	9/00; C07H 21/02, 21/04 and US	S Cl.: 435/5, 7.9, 183; 536/23.1, 23.2, 23.72
MERKE & CO., INC		
This international prelimit Examining Authority and	nary examination report has be is transmitted to the applicant	en prepared by this International Preliminary according to Article 36.
2. This REPORT consists of	a total of <u>sheets</u> , including	g this cover sheet.
which have been ame	ended and are the basis for this	., sheets of the description, claims and/or drawings s report and/or sheets containing rectifications made 507 of the Administrative Instructions under the PCT).
These annexes consist of a	a total of sheets.	
3. This report contains indica	ations relating to the following	; items:
I Basis of the rep	oort	
II Priority		
III Non-establishm	ent of report with regard to no	ovelty, inventive step and industrial applicability
IV Lack of unity o	f invention	
V Reasoned states	ment under Article 35(2) with itations and explanations suppo	regard to novelty, inventive step or industrial orting such statement
VI Certain docume		
VII Certain defects	in the international application	n.
VIII Certain observa	ations on the international appl	lication
Date of submission of the demand	Dat	e of completion of this report
05 November 2003 (05.11.2003)	23 1	December 2003 (23.12.2003)
Name and mailing address of the IPEA/ Mail Stop PCT, Attn: IPEA/US	US	horized officer D. Roberts of Roberts
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 223 13-1450	[CTe]	chand Saidha U ephone No. (703) 308-0196
Facsimile No. (703)305-3230		* N. /

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application	
PCT/US03/12509	

	Basis of the report
1.	With regard to the elements of the international application:*
	the international application as originally filed. the description: pages 1-24 as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of the claims: pages 25-28, as originally filed pages NONE, as amended (together with any statement) under Article 19 pages NONE, filed with the demand
	pages NONE , filed with the letter of
	the drawings: pages 1-12, as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of the sequence listing part of the description: pages 1-6, as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language which is: the language of a translation furnished for the purposes of international search (under Rule23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination(under Rules 55.2 and/or 55.3). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
١	contained in the international application in printed form.
	filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.
	furnished subsequently to this Authority in computer readable form.
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international ambigation as filed has been furnished.
	The statement that the information recorded in computer readable form is identical to the written sequence insumption has been furnished.
	4. The amendments have resulted in the cancellation of:
	the claims, Nos. NONE the drawings, sheets/fig NONE This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).** * Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to it this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). * Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

Form PCT/IPEA/409 (Box I) (July 1998)

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. STATEMENT Novelty (N) Claims 1-26 NONE NO Inventive Step (IS) Claims 1-26 Claims NONE NO Industrial Applicability (IA) Claims 1-26 Claims NONE NO Industrial Applicability (IA) Claims 1-26 NONE NO Claims 1-26 NONE NO Claims 1-26 NONE NO Claims 1-26 NONE NO NO 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Novelty (N) Claims Claims NONE Inventive Step (IS) Claims Claims Claims 1-26 YE NONE NO Industrial Applicability (IA) Claims NONE NO Claims 1-26 YE NONE NO Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Inventive Step (IS) Claims NONE Claims 1-26 Claims NONE Industrial Applicability (IA) Claims 1-26 Claims NONE NO Industrial Applicability (IA) Claims 1-26 Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Inventive Step (IS) Claims 1-26 Claims NONE Industrial Applicability (IA) Claims 1-26 Claims NONE Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Industrial Applicability (IA) Claims NONE NO Claims 1-26 Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Industrial Applicability (IA) Claims NONE NO Claims 1-26 Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Industrial Applicability (IA) Claims 1-26 Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
2. CITATIONS AND EXPLANATIONS Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Claims 1-26 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell construct or a chimeric HCV replicon contruct containing a 3'UTR based on the HCV-la 3'UTR. The closest prior art works of Houghton et al. (1999), Lohmann et al. (2001), Pietschmann et al. (2001) or Lohmann et al. (1999), either alone or in combination do not teach or make the invention obvious.
Claims 1-26 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimer can be made or used in industry.
·

Form PCT/IPEA/409 (Box V) (July 1998)